ArticleGastrointestinal cancer research : GCR2008
The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.Journal of gastrointestinal cancer · 2024Article
- Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.Digestive diseases and sciences · 2022Article
- Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.JAMA network open · 2021Article
- Article
- Clinical implication of the innovations of the 8Journal of thoracic disease · 2018Article
- Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.The British journal of surgery · 2017Article
- Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update.Nagoya journal of medical science · 2017Review
- Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.Oncotarget · 2017Review
- Multimodal treatment of gastric cancer in the west: Where are we going?World journal of gastroenterology · 2015Review
- Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.World journal of gastroenterology · 2013Article
- Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.Journal of hematology & oncology · 2013Review
- [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Adjuvant treatment for gastric cancer: chemotherapy versus radiation.The oncologist · 2013Review
- FDG-PET/CT based response-adapted treatment.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Review
- Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates.Molecular imaging and biology · 2012Article
- Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients.Langenbeck's archives of surgery · 2012Article
- FDG PET imaging in the staging and management of gastric cancer.Journal of gastrointestinal oncology · 2011Article
- Biological imaging in the assessment of neoadjuvant treatment response in esophageal cancer: a new era?Gastrointestinal cancer research : GCR · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative induction therapy in stages II and III adenocarcinoma of the esophagogastric junction (AEG) and gastric cancer is now an accepted treatment choice in the Western world. Patients who respond to induction therapy have significantly improved survival compared to nonresponding patients. Until recently, however, no prospectively tested markers for predicting response and/or prognosis in this settingwere available. The MUNICON I study recently showed the utility of fluorodeoxyglucose-positron emission tomography (FDG-PET) in predicting response and prognosis in AEG and indicated the feasibility of a PET-guided treatment algorithm. These findings are an important step forward in tailoring multimodal treatment to tumor biology. In gastric cancer, the issue is more complicated, because approximately 30% of these cancers cannot be visualized with sufficient contrast for quantification. Insufficient FDG uptake is mostly associated with diffusetype gastric cancer with signet cells and mucinous content. In FDG avid patients, FDG-PET can be used for response evaluation. The prognosis of nonavid patients is similar to metabolic nonresponders. The addition of new tracers (eg, fluorothymidine) might increase the accuracy of these tests in the future. In AEG types I and II, PET-guided induction therapy is feasible and will undergo further evaluation in a randomized multicenter trial. In gastric cancer, there should be consideration of such treatment concepts as immediate resection after 2 weeks of induction therapy with or without adjuvant treatment in metabolic nonresponders or modified chemotherapy regimens possibly including biologically targeted drugs in FDG non-avid tumors.
Identifiers
19259277PMC2632563W2205454444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.